ArticleNature biotechnology2017
First approval in sight for Novartis' CAR-T therapy after panel vote.
Article in Nature biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- In situ generation of proinflammatory CAR macrophages via mRNA-TLR agonist co-delivery for triple-negative breast cancer immunotherapy.Journal for immunotherapy of cancer · 2026Article
- The renaissance ofFrontiers in immunology · 2026Review
- Analysis of Hepatic Lentiviral Vector Transduction: Implications for Preclinical Studies and Clinical Gene Therapy Protocols.Viruses · 2025Article
- Analysis of hepatic lentiviral vector transduction; implications for preclinical studies and clinical gene therapy protocols.bioRxiv : the preprint server for biology · 2024Article
- Advances in research based on antibody-cell conjugation.Frontiers in immunology · 2023Review
- IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma.Molecular therapy oncolytics · 2022Article
- T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.Nature biomedical engineering · 2021Article
- Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells.Cancer cell international · 2021Article
- A novel endogenous CD16-Expressing Natural Killer Cell for cancer immunotherapy.Biochemistry and biophysics reports · 2021Article
- A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology.Cancers · 2021Article
- Review
- Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.Oncoimmunology · 2021Article
- Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB.Pharmaceutics · 2020Review
- Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by γδ T Cells in Contrast to αβ T Cells.Molecular therapy oncolytics · 2020Article
- Targeting EphA2 in cancer.Journal of hematology & oncology · 2020Review
- Engineering adeno-associated virus vectors for gene therapy.Nature reviews. Genetics · 2020Review
- Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.BioMed research international · 2020Review
- Bugs as Cancer Drugs: Challenges and Opportunities.Molecular and cellular biology · 2019Article
- Radioactive drugs emerge from the shadows to storm the market.Nature biotechnology · 2018Article
- Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization.Gene therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28787408What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.